Thyroid cancer: delaying radioiodine therapy safe to 180 days postsurgery

  • Kim M & al.
  • Clin Endocrinol (Oxf)
  • 18 May 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Delaying radioactive iodine (RAI) therapy after total thyroidectomy (TT) up to 180 days did not affect recurrence or mortality outcomes of patients with intermediate- to high-risk papillary thyroid carcinoma (PTC), according to a retrospective study.

Why this matters

  • The association between RAI timing and outcomes is unclear.

Key results

  • Patients who received RAI
  • Delayed RAI was not significantly associated with worse DFS (HR, 1.3; P=.061) or OS (HR, 1.5; P=.388) compared with early RAI.

Study design

  • 720 patients with PTC who received RAI after TT, 360 at
  • Funding: None.

Limitations

  • Retrospective study.
  • Longer RAI delays were not analyzed.